康方生物(09926)拟配售2355万股一级配售股份

Group 1 - The company, CanSino Biologics (康方生物), announced a conditional agreement for a primary placement of 23.55 million shares at a price of HKD 149.54 per share, which represents approximately 2.62% of the company's issued share capital as of the announcement date [1] - The placement price reflects a discount of about 4.75% compared to the closing price of HKD 157.00 on August 27, 2025, the last trading day before the placement agreement [1] - The estimated total gross proceeds from the placement are approximately HKD 3.522 billion, with net proceeds expected to be around HKD 3.493 billion after deducting commissions and other related expenses [1] Group 2 - The board was informed that Dr. Xia Yu and Dr. Li Baiyong, as sellers, entered into a secondary placement agreement on August 28, 2025, to sell a total of 3 million existing shares, representing about 0.33% of the total issued shares as of the announcement date [2]